HB 1487-2_ Filed 02/26/2001, 16:52
Text Box
Adopted Rejected
[
]
COMMITTEE REPORT
YES:
26
NO:
0
MR. SPEAKER:
Your Committee on Ways and Means , to which was referred House Bill 1487 ,
has had the same under consideration and begs leave to report the same back to the House with
the recommendation that said bill be amended as follows:
Delete the committee report of the Public Health Committee
adopted February 8, 2001.
SOURCE: Page 1, line 3; (01)AM148702.1. -->
Page 1, line 3, strike "subsection (c)," and insert " subsections (c)
and (d),".
Page 1, line 12, delete "significant medical".
Page 1, line 13, delete "illness, death, or".
Page 1, between lines 14 and 15, begin a new line block indented
and insert:
" (8) Congenital adrenal hyperplasia.
(9) Biotinidase deficiency.
(10) Disorders detected by tandem mass spectrometry, if the
state department determines that the technology is available
for use by a designated laboratory under section 7 of this
chapter.".
Page 2, after line 3, begin a new paragraph and insert:
" (d) The examinations under subsection (a)(10) are not
required until the state department determines that there are
sufficient funds in the newborn screening fund from
appropriations from the general assembly and gifts and grants to
the fund for the state department to pay for the cost of the tests
performed under subsection (a)(10).
SOURCE: IC 16-41-17-10; (01)AM148702.2. -->
SECTION 2.
IC 16-41-17-10
IS AMENDED TO READ AS
FOLLOWS [EFFECTIVE JULY 1, 2001]: Sec. 10. (a) The state
department shall develop the following:
(1) A registry for tracking and follow-up of all newborns and
individuals for screening.
(2) A centralized program that provides follow-up, diagnosis,
management, and family counseling and support, including
equipment, supplies, formula, and other materials, for all infants
and individuals identified as having one (1) of the disorders listed
in section 2 of this chapter.
(3) A laboratory quality assurance program, including
proficiency testing.
(4) A statewide network of genetic evaluation and counseling
services.
(5) A system for using, for epidemiological survey and research
purposes, any waste blood specimen generated under this
chapter.
(b) The program described in subsection (a) shall be funded by
collection of a newborn screening fee for each newborn screened by
a designated laboratory.
(c) The state department shall set the fee and procedures for
disbursement under rules adopted under
IC 4-22-2.
The fee must be
based upon the projected cost of the program. The state department
may not assess the part of the fee that is attributable to tests that
are performed under section 2(a)(10) of this chapter. The proposed
fee must be approved by the budget agency before the rule is adopted.
(d) The designated laboratory shall assess, collect, and deposit the
fees established under subsection (c) in the newborn screening fund
established under section 11 of this chapter.
(e) The state department shall annually review:
(1) the newborn screening fee; and
(2) the fee assessed by each designated laboratory for testing
under section 2(a)(1) through 2(a)(9) of this chapter.
(f) Waste blood specimens used for the purpose of implementing the
system described under subsection (a)(5) may not include the name or
other identifying characteristics that would identify the individual
submitting the specimen.
SOURCE: IC 16-41-17-11; (01)AM148702.3. -->
SECTION 3.
IC 16-41-17-11
IS AMENDED TO READ AS
FOLLOWS [EFFECTIVE JULY 1, 2001]: Sec. 11. (a) The newborn
screening fund is established for the purpose of carrying out this
chapter. The state department shall administer the fund.
(b) The expenses of the newborn screening program shall be paid
from money in the fund. The expenses of performing the tests under
section 2(a)(10) of this chapter shall be paid from money in the
fund subject to section 2(d) of this chapter.
(c) Money in the fund at the end of a state fiscal year does not revert
to the state general fund.
(d) The fund consists of appropriations from the general
assembly, fees assessed under this chapter, and gifts and grants to
the fund.
SOURCE: ; (01)AM148702.4. -->
SECTION 4. [EFFECTIVE JULY 1, 2001]
(a) The state
department of health shall develop the following:
(1) Criteria for a laboratory to qualify as a designated
laboratory under
IC 16-41-17-7
to test for disorders
detectable through the use of tandem mass spectrometry
under
IC 16-41-17-2
(a)(10), as amended by this act, and to
test for the disorders listed under
IC 16-41-17-2
(a)(1) through
IC 16-41-17-2
(a)(9), as amended by this act.
(2) A process for designating one (1) or more qualified
laboratories to serve as a designated laboratory under
IC 16-41-17-7
to test for disorders detectable through the use
of tandem mass spectrometry under
IC 16-41-17-2
(a)(10), as
amended by this act, and to test for the disorders listed under
IC 16-41-17-2
(a)(1) through
IC 16-41-17-2
(a)(9), as amended
by this act.
(b) Except as provided in subsection (c), after the state
department of health has developed the qualifying criteria in
subsection (a)(1) and the designating processes in subsection (a)(2),
the state department of health may designate one (1) or more
qualified laboratories under
IC 16-42-17-7
to test for disorders
detectable through the use of tandem mass spectrometry under
IC 16-41-17-2
(a)(10), as amended by this act, and to test for the
disorders listed under
IC 16-41-17-2
(a)(1) through
IC 16-41-17-2
(a)(9), as amended by this act. A designated
laboratory may use tandem mass spectrometry to test for those
disorders listed under
IC 16-41-17-2
(a)(1) through
IC 16-41-17-2
(a)(9), as amended by this act, that are detectable
through the use of tandem mass spectrometry.
(c) The state department of health may not designate a
laboratory to test for disorders detectable through the use of
tandem mass spectrometry under
IC 16-41-17-2
(a)(10), as
amended by this act, until funds have been received by the state
department of health to pay for the tests under
IC 16-41-17-2
(a)(10), as amended by this act.
(d) The state department of health shall apply for a grant
through the federal Public Health Service Act and any other
federal grants available to expand or improve programs to provide
screening, testing, or other specialty services for newborns or
children at risk of disorders detectable through the use of tandem
mass spectrometry.
(e) This SECTION expires July 1, 2006.".
(Reference is to HB 1487 as introduced, and as amended by the
committee report of the Public Health Committee on February 8, 2001.)
and when so amended that said bill do pass.
__________________________________
AM148702/DI 92 2001